Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 12/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 8/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748730 | 0.90 | PIK3CA (0.41) | PIK3CAPIK3CDACACBPSEN1PSEN2 | |
| SCHEMBL30748972 | 0.84 | PSEN1 (0.40) | PIK3CAPIK3CDACACBPSEN1PSEN2 | |
| SCHEMBL30748881 | 0.83 | PIK3CA (0.38) | PIK3CAPIK3CDACACBPSEN1PSEN2 | |
| SCHEMBL30748866 | 0.82 | PIK3CD (0.36) | PIK3CAPIK3CDACACBPSEN1PSEN2 | |
| SCHEMBL30748851 | 0.74 | NAAA (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3333248 | 0.67 | ACACB (0.48) | ACACBHRH3 | |
| SCHEMBL4767310 | 0.66 | MAPT (0.51) | ACACB | |
| SCHEMBL796604 | 0.66 | MAPT (0.51) | ACACB | |
| SCHEMBL20000628 | 0.66 | ACACB (0.47) | ACACBHRH3 | |
| SCHEMBL30749115 | 0.65 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | PIK3CA 1906/4885PIK3CD 3772/4885ACACB 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.